OncRef

Clinical Trial: NCT05061550

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2026-10-21

Study Overview

Brief Summary

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Official Title

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Durvalumab
  • Drug: Oleclumab
  • Drug: Monalizumab
  • Drug: Dato-DXd
  • Drug: AZD0171
  • Drug: Carboplatin
  • Drug: Cisplatin
  • Drug: Pemetrexed/Cisplatin
  • Drug: Pemetrexed/Carboplatin
  • Drug: Carboplatin/Paclitaxel
  • Drug: Volrustomig
  • Drug: Rilvegostomig

Other Study ID Numbers

  • D9077C00001
  • 2023-508852-21-00
  • 2021-003369-37
  • 2023

Start Date (Actual)

2022-04-14

Primary Completion Date (Estimated)

2030-05-28

Study Completion Date (Estimated)

2030-05-28

Enrollment (Estimated)

630

Study Type

Interventional

Phase

Phase 2